Evidence for the upregulation of osteogenic protein-1 mRNA expression in musculoskeletal neoplasms

Journal of Orthopaedic Research

Volumn 16, Issue 1, 1998, Pages 8-14

  Weber, K L ^a   Bolander, M E ^a   Rock, M G ^a   Pritchard, D ^a   Sarkar, G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ENZYMES; MUSCULOSKELETAL SYSTEM; ONCOLOGY; RNA;

REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

GENETIC ENGINEERING;

ESTROGEN RECEPTOR; MESSENGER RNA; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BONE TUMOR; BREAST CANCER; CANCER SCREENING; CASE REPORT; CHONDROSARCOMA; FEMALE; GENE SEQUENCE; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

EID: 0031979858     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.1100160103     Document Type: Article

References (33)

1. 1 Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Giriffiths CT, Parker L, Zurawski VR Jr, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883–887, 1983
2. 2 Bishop JM: The molecular genetics of cancer. Science 235: 305–311, 1987
3. 3 Carbone M, Rizzo P, Procopio A, Giuliano M, Pass HI, Gebhardt MC, Mangham C, Hansen M, Malkin DF, Bushart G, Pompetti F, Picci P, Levine AS, Bergsagel D, Garcea RL: SV40‐like sequences in human bone tumors. Oncogene 13: 527–535, 1996
4. 4 Chomczynski P, Sacchi N: Single‐step method of RNA isolation by acid guanidinium thiocyanate‐phenol‐chloroform extraction. Anal Biochem 162: 156–159, 1987
5. 5 Cooper CS: Translocations in solid tumors. Curr Op Genet Dev 6: 71–75, 1996
6. 6 Dalat BI, Keown PA, Greenberg AH: Immunocytochemical localization of secreted transforming growth factor‐β 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143: 381–389, 1993
7. 7 Derynck R: TGF‐β receptor‐mediated signaling. Trends Biochem Sci 19: 548–553, 1994
8. 8 Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC: Transforming growth factor‐beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73: 628–635, 1995
9. 9 Ellingsworth LR, Brennan JE, Fok K, Rosen DM, Bentz H, Piez KA, Seyedin SM: Antibodies to the N‐tcrminal portion of cartilage‐inducing factor A and transforming growth factor beta: immunohistochemical localization and association with differentiating cells. J Biol Chem 261: 12362–12367, 1986
10. 10 Gebhardt MC: Molecular biology of sarcomas. Orthop Clin North Am 3: 421–429, 1996
11. 11 Groffen J, Stephenson JR, Heisttrkamp N, de Klein A, Bartram CR, Grosveld G: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93–99, 1984
12. 12 Ivanovic V, Melman A, Davis‐Joseph B, Valcic M, Geliebter J: Letter to the editor. Elevated plasma levels of TGF‐β 1 in patients with invasive prostate cancer. Nature Medicine 1 ; 282–284, 1995
13. 13 Kantoff PW, Talcott JA: The prostate specific antigen: its use as a tumor marker for prostate cancer. Hcmatol Oncol Clin North Am 8: 555–572, 1994
14. 14 Kingsley DM: The TGF‐β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8: 133–146, 1994
15. 15 Kurzrock R, Kloetzer WS, Talpaz M, Blick M, Walters R, Arlinghaus R, Gutterman JU: Identification of molecular variants of p210 bcr‐abl in chronic myelogenous leukemia. Blood 70: 23–236, 1987
16. 16 Larramendy ML, Tarkkanen M, Valle J, Kivioja AH, Ervasti H, Karaharju E, Salmivalli T, Elomaa I, Knuutila S: Gains, losses and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 150: 685–691, 1997
17. 17 Massague J: The transforming growth factor‐β family. Ann Rev Cell Biol 6: 597–641, 1990
18. 18 Miki Y, Swensen J, Shattuck‐Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen‐Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvcring L, Morrison J. Rosteck P, Lai M, Barrett C, Lewis C, Neuhausen S, Cannon‐Albright L, Goldgal D, Wiseman R, Kamb A, Skolnick MI: A strong candidate For the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71, 1994
19. 19 Nowell PC: The clonal evolution of tumor cell populations. Science 194: 23–28, 1976
20. 20 Posner MR, Mayer RJ: The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am 8: 533–553, 1994
21. 21 Robey PG, Termine JD: Human bone cells in vitro. Calcif Tissue Int 37: 453–460, 1985
22. 22 Sandberg M, Vuorio T, Hirvonen H, Alitalo K, Vuorio E: Enhanced expression of TGF‐β and c‐fos mRNAs in the growth plates of developing human long bones. Development 102: 461–470, 1988
23. 23 Seyedin SM, Thomas TC, Thompson AY, Rosen DM, Piez KA: Purification and characterization of two cartilage‐inducing factors from bovine demineralized bone. Proc Natl Acad Sci U S A 82: 2267–2271, 1985
24. 24 Steiner MS, Barrack ER: Transforming growth factor‐beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrnol 6: 15–25, 1992
25. 25 Steiner MS, Zhou ZZ, Tonb DC, Barrack ER: Expression of transforming growth factor‐beta 1 in prostate cancer. Endocrinology 135: 2240–2247, 1994
26. 26 Stenman G, Andersson H, Mandahl N, Meis‐Kindblom JM, Kindblom LGvTranslocation t(9; 22) (q22; ql2) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer 62: 398–402, 1995
27. 27 Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck‐Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa‐Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur‐Morrison J, Nguyen K. Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver‐Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon‐Albright L, LaBrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE: The complete BRCA2 gene and mutations in chromosome 13q‐linked kindreds. Nature Genetics 12: 333–337, 1996
28. 28 Tiemann F, Deppert W: Immortalization of BALB/c mouse embryo fibroblasts alters SV40 large T‐antigen interactions with the tumor suppressor p53 and results in a reduced SV40 transformation‐efficiency. Oncogene 9: 1907–1915, 1994
29. 29 Weinberg RA: Tumor suppressor genes. Science 254: 1138–1146, 1991
30. 30 Welch DR, Fabra A, Nakajima M: Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A 87: 7678–7682, 1990
31. 31 Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792, 1995
32. 32 Yamada N, Kato M, ten Dijke P, Yamashita H, Sampath TK, Heldin C‐H, Miyazono K, Funa K: Bone morphgenetic protein type IB receptor is progressively expressed in malignant glioma tumours. Br J Cancer 73: 624–629, 1996
33. 33 Yoshikawa H, Rettig WJ, Takaoka K, Alderman E, Rup B, Rosen V, Wozney JM, Lane JM, Huvos AG, Garin‐Chesa P: Expression of bone morphogenetic proteins in human osteosarcoma. Cancer 73: 85–91, 1994